| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
ADR |
| Shares
Out: |
58,240,000 |
| Market
Cap: |
931.26(M) |
| Last
Volume: |
115,349 |
Avg
Vol: |
115,030 |
| 52
Week Range: |
$9.64 - $17.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,000 |
41,000 |
370,500 |
| Total Buy Value |
$0 |
$29,000 |
$558,597 |
$1,422,084 |
| Total People Bought |
0 |
1 |
4 |
6 |
| Total Buy Transactions |
0 |
1 |
5 |
18 |
| Total Shares Sold |
0 |
75,000 |
103,975 |
103,975 |
| Total Sell Value |
$0 |
$1,089,750 |
$1,522,364 |
$1,522,364 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
2 |
2 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mccamish Mark Anthony |
Director |
– • – |
2020-09-16 |
4 |
B |
$5.73 |
$679,969 |
I/I |
118,602 |
118,602 |
2.1 |
30% |
|
| Mchugh Thomas S |
Chief Financial Officer |
• – – |
2020-08-28 |
4 |
B |
$6.77 |
$50,777 |
D/D |
7,500 |
17,500 |
2.74 |
-5% |
|
| Glass Geoffrey Michael |
Director |
– • – |
2020-08-28 |
4 |
B |
$6.78 |
$32,560 |
D/D |
4,800 |
65,700 |
2.39 |
-5% |
|
| Palczuk Linda |
Director |
– • – |
2020-08-14 |
4 |
B |
$7.94 |
$19,850 |
D/D |
2,500 |
37,900 |
2.39 |
-16% |
|
| Ende Eric J |
Director |
– • – |
2020-08-13 |
4 |
B |
$7.74 |
$38,928 |
D/D |
5,000 |
67,900 |
2.39 |
-11% |
|
| Mchugh Thomas S |
Chief Financial Officer |
• – – |
2020-08-13 |
4 |
B |
$7.78 |
$77,814 |
D/D |
10,000 |
10,000 |
2.74 |
-11% |
|
| Glass Geoffrey Michael |
Director |
– • – |
2020-08-13 |
4 |
B |
$7.76 |
$50,440 |
D/D |
6,500 |
60,900 |
2.39 |
-11% |
|
| Glass Geoffrey Michael |
Director |
– • – |
2020-08-12 |
4 |
B |
$7.70 |
$50,050 |
D/D |
6,500 |
54,400 |
2.39 |
-10% |
|
| Divis Greg J |
Chief Executive Officer |
• • – |
2020-08-12 |
4 |
B |
$7.78 |
$101,156 |
D/D |
13,000 |
99,100 |
2.81 |
-10% |
|
| Ende Eric J |
Director |
– • – |
2020-08-12 |
4 |
B |
$7.76 |
$116,355 |
D/D |
15,000 |
62,900 |
2.39 |
-10% |
|
| Hatten Sandra L |
See Remarks |
• – – |
2019-12-12 |
4 |
S |
$7.23 |
$22,211 |
D/D |
(3,072) |
55,765 |
|
- |
|
| Ende Eric J |
Director |
– • – |
2019-12-04 |
4 |
B |
$5.97 |
$59,700 |
D/D |
10,000 |
47,900 |
2.39 |
- |
|
| Palczuk Linda |
Director |
– • – |
2019-12-03 |
4 |
B |
$5.91 |
$44,325 |
D/D |
7,500 |
35,400 |
2.39 |
- |
|
| Glass Geoffrey Michael |
Director |
– • – |
2019-11-18 |
4 |
B |
$4.99 |
$74,850 |
D/D |
15,000 |
47,900 |
2.39 |
- |
|
| Ende Eric J |
Director |
– • – |
2019-11-15 |
4 |
B |
$4.98 |
$49,762 |
D/D |
10,000 |
37,900 |
2.39 |
- |
|
| Divis Greg J |
Chief Executive Officer |
• – – |
2019-11-15 |
4 |
B |
$5.13 |
$97,470 |
D/D |
19,000 |
86,100 |
2.74 |
- |
|
| Glass Geoffrey Michael |
Director |
– • – |
2019-11-15 |
4 |
B |
$4.99 |
$24,950 |
D/D |
5,000 |
32,900 |
2.39 |
- |
|
| Divis Greg J |
See Remarks |
• – – |
2019-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
67,100 |
|
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2019-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,837 |
|
- |
|
| Kanan Michael F |
See Remarks |
• – – |
2019-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
50,538 |
|
- |
|
| Thompson Phillandas T. |
See Remarks |
• – – |
2019-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
113,671 |
|
- |
|
| Ende Eric J |
Director |
– • – |
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,900 |
27,900 |
|
- |
|
| Broadfin Healthcare Master Fund Ltd |
Director |
– • – |
2019-01-31 |
4 |
A |
$0.00 |
$0 |
I/I |
27,900 |
3,130,573 |
|
- |
|
| Kanan Michael F |
See Remarks |
• – – |
2018-12-14 |
4 |
S |
$2.49 |
$21,022 |
D/D |
(8,429) |
29,538 |
|
- |
|
| Gusky David P |
Controller & CAO |
• – – |
2018-12-14 |
4 |
S |
$2.68 |
$1,656 |
D/D |
(617) |
4,083 |
|
- |
|
186 Records found
|
|
Page 2 of 8 |
|
|
